Knight Therapeutics Reports First Quarter 2025 Results

About this update from Knight Therapeutics, Inc.

[{"type":"text","content":"Knight Therapeutics Reports First Quarter 2025 Results\n\n\n\n MONTREAL, May 08, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (\"Knight\" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2025. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.\n \n\n\n Q1-25 Highlights\n \n\n\n\n Financial results\n \n\n\n\n Revenues were $88,076, an increase of $1,472 or 2% over the same period in prior year. The increase was driven by the growth of our key promoted products including our recent launches, partly offset by declines of our mature products and the depreciation of select LATAM currencies.\n \n\n Gross margin was $34,866 or 40% of revenues compared to $41,699 or 48% of revenues in the same period in prior year. The decrease was driven by the impact of the hyperinflation accounting in Argentina.\n \n\n Operating loss was $5,537 compared to an operating income of $2,660 in the same period in prior year.\n \n\n Net income was $2,185, compared to a net loss $4,546 in the same period in prior year.\n \n\n Earnings per share was $0.02, compared to a loss per share of $0.04 in the same period in prior year.\n \n\n Cash inflow from operations was $3,670, a decrease of $27,211 or 88% over prior year.\n \n\n\n\n\n Non-GAAP measures\n \n\n\n\n Adjusted Revenues\n \n 1\n \n were $87,979, an increase of $2,184 or 3% or $6,631 or 8% on a constant currency\n \n 1\n \n basis, driven by the growth of our key promoted products including our recent launches, partly offset by declines of our mature products.\n \n\n Adjusted Gross margin\n \n 1\n \n was $40,934 or 47% of Adjusted Revenues\n \n 1\n \n compared to $40,695 or 47% of Adjusted Revenues\n \n 1\n \n in the same period in prior year.\n \n\n Adjusted EBITDA\n \n 1\n \n was $12,113, a decrease of $1,476 or 11% over the same period in prior year.\n \n\n Adjusted EBITDA per share\n \n 1\n \n was $0.12, a decrease of $0.01 or 8% over the same period in prior year driven by a decrease in the Adjusted EBITDA\n \n 1\n \n offset by the impact of the common shares purchased through the NCIB.\n \n\n\n\n\n Corporate developments\n \n\n\n\n Entered into an asset purchase agreement with Endo Oper...

More updates from Knight Therapeutics, Inc.